The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma

Oncoimmunology. 2015 Jan 30;4(1):e955683. doi: 10.4161/21624011.2014.955683. eCollection 2015 Jan.

Abstract

The melanoma-associated antigens Melan-A and NY-ESO-1 stimulate different T-cell responses in late-stage melanoma patients. Either CD4+ or CD8+ T-cell reactivity against NY-ESO-1 was associated with better prognosis, but for Melan-A, only CD8+ but not CD4+ T-cell responses were associated with longer survival.

Keywords: MAGE-A3; Melan-A; NY-ESO-1; antigen-specific T-cells; intracellular cytokine staining; survivin.